Contact
searchSearch
HMP Global
Login

News

Annalice Gandini, IRCCS
Videos
Real-World Neoadjuvant Immunotherapy Demonstrates High Response Rates in dMMR/MSI Colorectal Cancer
07/14/2026
Annalice Gandini
Annalice Gandini, IRCCS, discusses results from the real-world AGEO-NEO-MSI study which demonstrated that neoadjuvant immunotherapy produced high complete response rates in patients with nonmetastatic dMMR/MSI-H colorectal cancer while...
Annalice Gandini, IRCCS, discusses results from the real-world AGEO-NEO-MSI study which demonstrated that neoadjuvant immunotherapy produced high complete response rates in patients with nonmetastatic dMMR/MSI-H colorectal cancer while...
Annalice Gandini, IRCCS,...
07/14/2026
Oncology
News
Adagrasib Plus Cetuximab Does Not Improve Progression-Free or Overall Survival Over Chemotherapy in KRAS G12C–Mutated Metastatic Colorectal Cancer
07/07/2026
Stephanie Holland
The phase 3 KRYSTAL-10 trial did not demonstrate significant improvements in progression-free or overall survival with adagrasib plus cetuximab versus standard second-line chemotherapy in patients with KRAS G12C-mutated metastatic colorectal...
The phase 3 KRYSTAL-10 trial did not demonstrate significant improvements in progression-free or overall survival with adagrasib plus cetuximab versus standard second-line chemotherapy in patients with KRAS G12C-mutated metastatic colorectal...
The phase 3 KRYSTAL-10 trial did...
07/07/2026
Oncology
Eiji Oki, MD, PhD, FACS
Videos
ctDNA Dynamics Predict Outcomes After Adjuvant Chemotherapy in Patients With Colorectal Cancer
06/09/2026
Eiji Oki, MD, PhD
Eiji Oki, MD, PhD, discusses results from the CIRCULATE-Japan trial showing that serial ctDNA dynamics during adjuvant chemotherapy strongly predict recurrence risk and may help personalize treatment strategies in colorectal cancer.
Eiji Oki, MD, PhD, discusses results from the CIRCULATE-Japan trial showing that serial ctDNA dynamics during adjuvant chemotherapy strongly predict recurrence risk and may help personalize treatment strategies in colorectal cancer.
Eiji Oki, MD, PhD, discusses...
06/09/2026
Oncology
Scott Kopetz, MD, PhD
Videos
Encorafenib and Cetuximab Plus FOLFIRI Improves Outcomes in BRAF V600E-Mutant Metastatic Colorectal Cancer
06/04/2026
Scott Kopetz, MD, PhD
Scott Kopetz, MD, PhD, FASCO, discusses phase 3 BREAKWATER Cohort 3 results showing that first-line encorafenib plus cetuximab and FOLFIRI improved response rates, progression-free survival, and overall survival vs standard therapy in BRAF...
Scott Kopetz, MD, PhD, FASCO, discusses phase 3 BREAKWATER Cohort 3 results showing that first-line encorafenib plus cetuximab and FOLFIRI improved response rates, progression-free survival, and overall survival vs standard therapy in BRAF...
Scott Kopetz, MD, PhD, FASCO,...
06/04/2026
Oncology
News
BREAKWATER Expands First-Line Treatment Options for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer
05/31/2026
Stephanie Holland
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib,...
05/31/2026
Oncology
News
Trastuzumab Rezetecan Shows Strong Clinical Promise in HER2-Positive Advanced Colorectal Cancer
05/27/2026
Emily Estrada
According to results from a phase 3 trial, trastuzumab rezetecan significantly improved survival and response in chemotherapy-refractory HER2-positive advanced colorectal cancer.
According to results from a phase 3 trial, trastuzumab rezetecan significantly improved survival and response in chemotherapy-refractory HER2-positive advanced colorectal cancer.
According to results from a...
05/27/2026
Oncology
News
Trastuzumab Rezetecan Shows Strong Clinical Promise in HER2-Positive Advanced Colorectal Cancer
05/27/2026
Emily Estrada
According to results from a phase 3 trial, trastuzumab rezetecan significantly improved survival and response in chemotherapy-refractory HER2-positive advanced colorectal cancer.
According to results from a phase 3 trial, trastuzumab rezetecan significantly improved survival and response in chemotherapy-refractory HER2-positive advanced colorectal cancer.
According to results from a...
05/27/2026
Oncology
News
Postsurgical ctDNA is Associated With Recurrence in Metastatic Colorectal Cancer
05/19/2026
Emily Estrada
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study...
05/19/2026
Oncology
News
Glecirasib Plus Cetuximab Shows Promise in KRAS G12C-Mutant Metastatic Colorectal Cancer
05/07/2026
Emily Estrada
Results from the phase 1/2 JAB-21822-1002 and JAB-21822-1007 trials demonstrated that glecirasib, a covalent KRAS G12C inhibitor, showed encouraging clinical activity both as monotherapy and in combination with cetuximab in patients with...
Results from the phase 1/2 JAB-21822-1002 and JAB-21822-1007 trials demonstrated that glecirasib, a covalent KRAS G12C inhibitor, showed encouraging clinical activity both as monotherapy and in combination with cetuximab in patients with...
Results from the phase 1/2...
05/07/2026
Oncology
News
Longitudinal ctDNA Analysis Identifies Patients With Poorer Outcomes in Metastatic Colorectal Cancer
05/07/2026
Emily Estrada
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from...
05/07/2026
Oncology

Recent News

News
NCCN Recommends Rusfertide as Category 1 Option Across Low- and High-Risk Polycythemia Vera
09/22/2026
Stephanie Holland
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines...
09/22/2026
Oncology
News
FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes
09/22/2026
Emily Estrada
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track...
09/22/2026
Oncology
News
Trastuzumab Deruxtecan Reduces Risk of Progression or Death in First-Line HER2-Mutant Non-Small Cell Lung Cancer
09/22/2026
Stephanie Holland
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3...
09/22/2026
Oncology
News
Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
09/21/2026
Emily Estrada
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3...
09/21/2026
Oncology
FDA Approval
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer
09/18/2026
Stephanie Holland
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase...
09/18/2026
Oncology
FDA Alerts
FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer
09/17/2026
Emily Estrada
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental...
09/17/2026
Oncology
News
Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma
09/17/2026
Emily Estrada
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE...
09/17/2026
Oncology
News
Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation
09/17/2026
Emily Estrada
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial...
09/17/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer
09/16/2026
Stephanie Holland
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3...
09/16/2026
Oncology
FDA Alerts
FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access
09/16/2026
Stephanie Holland
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing...
09/16/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use